KEYNOTE-199: Phase II Study of Pembrolizumab in Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer

June 1-5, 2018; Chicago, Illinois
In this phase II study, pembrolizumab showed antitumor activity in a subset of previously treated patients with metastatic CRPC regardless of PD-L1 expression status.
Format: Microsoft PowerPoint (.ppt)
File Size: 222 KB
Released: June 8, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Multidisciplinary commentary on optimal use of HER2-targeted treatment in early and metastatic breast cancer, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Kristi Kay Orbaugh, MSN, NP, AOCNP Danielle Roman, PharmD, BCOP Released: May 10, 2022

Two expert thoracic oncologists discuss novel anti-TIGIT immunotherapies for treatment of NSCLC, from Clinical Care Options (CCO)

person default Ani Balmanoukian, MD person default Jyoti D. Patel, MD Released: May 3, 2022

Diwakar Davar, MD, and Jyoti D. Patel, MD, discuss the role of TIGIT and emerging therapies for targeting TIGIT, including current trial data, from Clinical Care Options (CCO)

person default Diwakar Davar, MD person default Jyoti D. Patel, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 27, 2022 Expired: April 26, 2023

Diwakar Davar, MD, and Jyoti D. Patel, MD, review the role of TIGIT and investigational therapies being evaluated in solid tumors, from Clinical Care Options (CCO)

person default Diwakar Davar, MD person default Jyoti D. Patel, MD Released: April 27, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings